The Dow Jones closed slightly higher on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Cocrystal Pharma
- The Trade: Cocrystal Pharma, Inc. COCP Frost Gamma Investments Trust acquired a total 1,015,229 shares an average price of $1.97. To acquire these shares, it cost around $2 million.
- What’s Happening: Cocrystal Pharma posted a FY loss of $4.77 per share.
- What Cocrystal Pharma Does: Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses.
OncoCyte
- The Trade: OncoCyte Corporation OCX 10% owner Efrem Kamen acquired a total of 663,000 shares at an average price of $0.30. The insider spent around $200.03 thousand to buy those shares.
- What’s Happening: Oncocyte announced a $13.86 million public offering.
- What OncoCyte Does: OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.
Check This Out: Top 5 Utilities Stocks That You May Want To Dump In Q2
Xos
- The Trade: Xos, Inc. XOS Director George N Mattson acquired a total of 106,039 shares at an average price of $0.60. To acquire these shares, it cost around $64.08 thousand.
- What’s Happening: Xos posted a narrower-than-expected quarterly loss.
- What Xos Does: Xos Inc is an electric mobility company. It designs and develops fully electric battery mobility systems specifically for commercial fleets.
Don’t forget to check out our premarket coverage here
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.